Femasys Inc. FEMY
1.43 USD +0.01 (+0.70%)
At closeNov 10, 2026, 7:04 PM EST
1.43 0.00 0.00%
After hours · Nov 10, 7:04 PM ET
1.35 Day range 1.51
1.26 52-week range 22.20
- YTD
- -87.59%
- 1 year
- -93.13%
News
globenewswire.com Femasys Appoints John Moorhead to Board of Directors ATLANTA, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed…
globenewswire.com Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patients First in a planned network of specialty pharmacy…
benzinga.com Femasys Doubles Number Of Enrolling Facilities To 12 In Its FemBloc FINALE Pivotal Study Across U.S. Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand…
globenewswire.com Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control -- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval -- -- Twelve academic and private…
seekingalpha.com Femasys: Launch Is Funded. If The Sales Force Delivers, Then The Company Is In Tall Cotton. Femasys is a commercial-stage medtech company targeting OB/GYNs with in-office fertility and permanent birth control solutions. FEMY's $30M PIPE recapitalization ties full funding to commercial…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI)…
globenewswire.com Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo ATLANTA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed…
defenseworld.net Analyzing Haemonetics (NYSE:HAE) and Femasys (NASDAQ:FEMY) Femasys (NASDAQ: FEMY - Get Free Report) and Haemonetics (NYSE: HAE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) shares rose 124.1% to $3.63 during Wednesday's pre-market session. The company's market cap stands at $4.9 million. Tempest Therapeutics (NASDAQ:TPST) stock moved…
globenewswire.com Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women's Care -- Leading multi-site OB/GYN health practice to implement FemVue ® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026…
globenewswire.com Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio ATLANTA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed…
benzinga.com Femasys Files Prospectus Related To The Offer And Resale From Time To Time By The Selling Stockholders Of Up To An Aggregate Of 28,124,997 Shares Of Common Stock https://www.sec.gov/Archives/edgar/data/1339005/000114036126035625/ny20081537x1_s3.htm
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) shares moved…
benzinga.com Femasys Partners With UNC Health To Introduce Fertility Diagnostics, FemVue And SpermVue, Together With Femaseed Complete Within UNC Health OB/GYN Practice Locations -- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option --ATLANTA, Aug. 26, 2026 (GLOBE…
globenewswire.com Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations -- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue ® fertility evaluation and FemaSeed as a first-line treatment option -- ATLANTA, Aug. 26, 2026 (GLOBE…
benzinga.com Femasys Secures FDA Pathway for Non-Surgical Contraceptive The U.S. Food and Drug Administration (FDA) on Wednesday authorized the modular premarket approval application pathway for FemBloc, a non-surgical permanent birth control technology.
benzinga.com Femasys Secures FDA Pathway for Non-Surgical Contraceptive FDA clears modular PMA pathway for Femasys' FemBloc, an investigational non-surgical permanent birth control device for women in the US.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers ZeroStack (NASDAQ:ZSTK) stock increased by 440.2% to $9.94 during Wednesday's regular session. The company's market cap stands at $4.4 million. Tenon Medical (NASDAQ:TNON) shares moved…
- benzinga.com Femasys Q2 EPS $(1.08) Beats $(1.33) Estimate, Sales $756.716K Beat $730.667K Estimate Femasys (NASDAQ:FEMY) reported quarterly losses of $(1.08) per share which beat the analyst consensus estimate of $(1.33) by 18.8 percent. This is a 66.25 percent increase over losses of $(3.20) per…
- benzinga.com Maxim Group Maintains Buy on Femasys, Lowers Price Target to $10 Maxim Group analyst Jason McCarthy maintains Femasys (NASDAQ:FEMY) with a Buy and lowers the price target from $30 to $10.
globenewswire.com Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory program toward U.S. approval --…
globenewswire.com Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents -- New U.S. and international patents complement existing delivery system patents, extending global IP coverage for the FemBloc solution -- ATLANTA, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Femasys Inc.…
benzinga.com Femasys Announces $30M Private Placement Led By New Investors And Members Of Management Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand…
globenewswire.com Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million -- Potential proceeds would be received upon full cash exercise of warrants -- ATLANTA, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's regular session. The company's market cap stands at $36.8 million. Wellgistics Health (NASDAQ:WGRX) shares…
globenewswire.com Femasys Regains Compliance with Nasdaq Listing Requirements ATLANTA, June 24, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Femasys Announces CE Mark Approval For FemHSG Catheter, Further Expanding Its Portfolio In Europe Through Commercial Partners Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today…
globenewswire.com Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation -- -- New catheter complements FemVue® and supports streamlined in-office fertility evaluation --
globenewswire.com Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update -- With fertility rates at historic lows, Femasys advances access to early infertility care through FemaSeed® Complete, enabling OB/GYNs to treat patients within their own practices -- -- With…- benzinga.com Femasys Announces First Revenue-Generating Commercial Use Of Its Fertility Portfolio In An OBGYN Setting, Led By FemaSeed As A First-Line Infertility Treatment The procedure was supported by FemSperm®, enabling in-office sperm preparation and advancing the shift of fertility care to women's primary physician, where earlier intervention can improve access and
globenewswire.com Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete -- Integrated sperm preparation and intratubal insemination drive earlier intervention and streamlined, in-office care within routine OB/GYN practice -- ATLANTA, May 05, 2026 (GLOBE NEWSWIRE) --…
defenseworld.net Financial Analysis: CRISPR Therapeutics (NASDAQ:CRSP) and Femasys (NASDAQ:FEMY) CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) and Femasys (NASDAQ: FEMY - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based…- benzinga.com Femasys Collaborates With AMI Technologies To Roll Out, Commercialize Fertility Portfolio In Israel Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced…
benzinga.com Femasys Appoints John Canning COO Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced…- benzinga.com Femasys Q4 EPS $(0.06) Beats $(0.12) Estimate, Sales $813.387K Miss $1.450M Estimate Femasys (NASDAQ:FEMY) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.12) by 47.83 percent. This is a 73.91 percent increase over losses of $(0.23) per…
globenewswire.com Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update -- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating execution toward FemBloc® U.S. approval -- -- Enrollment underway in FDA-authorized FINALE pivotal trial demonstrating…- benzinga.com Femasys Initiates Participant Enrollment In FINALE Pivotal Clinical Study Of FemBloc Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced…
- benzinga.com Lake Street Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $1.5 Lake Street analyst Benjamin Haynor initiates coverage on Femasys (NASDAQ:FEMY) with a Buy rating and announces Price Target of $1.5.
globenewswire.com Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to…
benzinga.com Femasys' FemBloc Permanent Birth Control System Gets Certification Under Medical Device Single Audit Program -- FemBloc becomes the latest Femasys product to achieve MDSAP certification, building on a proven track record of compliance --ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY),…
benzinga.com Femasys Secures American Medical Association CPT Editorial Panel Approval For Category III CPT Code Covering Use Of FemaSeed For Intratubal Insemination -- Advances reimbursement strategy in the U.S. for FemaSeed, an intended first-step infertility treatment --ATLANTA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical…- benzinga.com Femasys Partners With OR Consulting Over Commercial Rollout Of Product Portfolio In Switzerland Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a new…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Femasys Gets Nasdaq's 180-Day Extension Through July 13 To Regain Compliance Femasys Inc. (NASDAQ: FEMY) ("Femasys" or the "Company"), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women…- benzinga.com Femasys Partners With Refuah Health Center To Offer FemaSeed As First Step In Infertility Treatment Process Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced today a…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Multi Ways Holdings Shares Are Trading Higher By Around 60%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session